Tag: Nasdaq:CGEM

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

- A word from our sponsors -

HomeTagsNasdaq:CGEM

Innventure to Participate in Upcoming Investor Conferences

Leverage Shares by Themes Launches 2X Long and 2X Short SpaceX ETFs Following Historic SpaceX IPO

Capital Bank Announces the Appointment of Don Busick to Its Board Leadership Team

Tag: Nasdaq:CGEM

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Explore

Press Releases

News & Opinion

Living

Others

Follow us